Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)
China flag China · Delayed Price · Currency is CNY
54.76
-2.90 (-5.03%)
May 8, 2026, 3:04 PM CST

SHE:002653 Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
60,74356,92736,88325,54523,69521,747
Market Cap Growth
35.34%54.35%44.38%7.81%8.96%16.68%
Enterprise Value
61,03857,84137,65826,25625,22722,521
Last Close Price
54.7651.3233.0022.7221.8419.79
PE Ratio
79.52219.3193.2786.5685.5263.02
Forward PE
77.6725.9225.9225.9225.9225.92
PS Ratio
12.0112.979.917.617.867.84
PB Ratio
12.5413.288.786.137.567.45
P/TBV Ratio
18.0220.5312.567.4510.1810.07
P/FCF Ratio
75.01125.3826513.18436.15--
P/OCF Ratio
54.4272.4383.4456.82250.62607.43
EV/Sales Ratio
12.0613.1810.127.838.378.12
EV/EBITDA Ratio
63.19125.0875.0148.2479.50122.44
EV/EBIT Ratio
88.89289.76143.7279.19178.20598.98
EV/FCF Ratio
75.37127.4027070.47448.29--
Debt / Equity Ratio
0.460.460.460.430.670.43
Debt / EBITDA Ratio
2.324.183.743.286.486.55
Debt / FCF Ratio
2.764.361373.2830.84--
Net Debt / Equity Ratio
0.060.140.170.120.430.23
Net Debt / EBITDA Ratio
0.311.281.400.884.213.67
Net Debt / FCF Ratio
0.371.31506.238.16-2.21-1.01
Asset Turnover
0.690.640.550.530.550.56
Inventory Turnover
4.004.383.843.103.053.91
Quick Ratio
1.771.561.481.501.090.81
Current Ratio
2.021.811.741.761.381.02
Return on Equity (ROE)
17.14%6.12%11.14%8.09%12.94%17.93%
Return on Assets (ROA)
5.88%1.81%2.44%3.26%1.60%0.47%
Return on Invested Capital (ROIC)
13.02%3.87%5.49%7.11%3.51%1.20%
Return on Capital Employed (ROCE)
11.40%3.70%5.00%6.40%3.10%1.10%
Earnings Yield
1.26%0.46%1.07%1.16%1.17%1.59%
FCF Yield
1.33%0.80%0.00%0.23%-2.56%-3.07%
Dividend Yield
0.49%0.52%1.26%0.88%-0.94%
Payout Ratio
23.34%128.34%106.72%14.43%89.32%123.52%
Buyback Yield / Dilution
1.70%0.11%-3.37%-2.57%1.17%0.07%
Total Shareholder Return
2.18%0.63%-2.11%-1.69%1.17%1.00%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.